Effect of Continuous Subcutaneous Foslevodopa/foscarbidopa Treatment on Falls, Posture and Freezing of Gait

被引：0

作者：

Odin, P. ^{[1
]}

Kimura, T. ^{[2
]}

Santos-Garcia, D. ^{[3
]}

Gandor, F. ^{[4
]}

Isaacson, S. ^{[5
]}

Saad, A. ^{[6
]}

Bergmann, L. ^{[6
]}

Gupta, R. ^{[6
]}

Kukreja, P. ^{[6
]}

Shah, M. ^{[6
]}

Pahwa, R. ^{[7
]}

机构：

[1] Lund Univ, Skane Univ Hosp, Div Neurol, Dept Clin Sci, Lund, Sweden

[2] Natl Hosp Org, Dept Neurol, Asahikawa Med Ctr, Asahikawa, Hokkaido, Japan

[3] Complejo Hospitalario Univ A Coruna, CHUAC, La Coruna, Spain

[4] Otto von Guericke Univ, Dept Neurol, Magdeburg, Germany

[5] Parkinsons Dis & Movement Disorders Ctr Boca Rato, Boca Raton, FL USA

[6] AbbVie Inc, North Chicago, CA USA

[7] Univ Kansas, Med Ctr, Kansas City, KS USA

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EPR-281

引用

页码：312 / 312

页数：1

共 44 条

[21] Stability and Predictability of Motor Symptom Control in Patients with Advanced Parkinson's Disease (aPD) Receiving Continuous Subcutaneous Foslevodopa/Foscarbidopa (LDP/CDP)
Pahwa, R.
Malaty, I.
Soileau, M.
Fung, V.
Garcia, D. Santos
Carroll, C.
Henriksen, T.
Epstein, A.
Yan, C.
Alobaidi, A.
Shewale, A.
Spiegel, A.
Facheris, M.
Shah, M.
Kukreja, P.
Zamudio, J.
Chaudhuri, K.
MOVEMENT DISORDERS, 2023, 38 : S44 - S45
[22] Pharmacokinetics, Safety and Tolerability of Foslevodopa/Foscarbidopa Following Continuous Subcutaneous Infusion to Arm, Thigh and Flank Compared to Abdomen in Parkinson's Disease Patients
Han, Y.
Kalluri, H.
Jeong, A.
Locke, C.
Facheris, M.
Gupta, S.
Rosebraugh, M.
MOVEMENT DISORDERS, 2023, 38 : S27 - S27
[23] Challenges with Oral Anti-Parkinsonian Medications and Opportunities with Continuous Subcutaneous Infusion (CSCI) Of Foslevodopa/Foscarbidopa (LDP/CDP) for Treatment of Advanced Parkinson's Disease (aPD)
Aldred, J.
Soileau, M.
Yan, C.
Brion, T.
Bellenger, A.
Suh, J.
O'Donnell, C.
Kukreja, P.
Facheris, M.
Shewale, A.
Kumar, R.
MOVEMENT DISORDERS, 2023, 38 : S8 - S9
[24] Levodopa Pharmacokinetics in Switching From Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson's Disease: A Case Report
Nukariya, Tomonori
Tezuka, Toshiki
Okusa, Shohei
Okochi, Ryotaro
Sakai, Yuto
Nihei, Yoshihiro
Nakahara, Jin
Seki, Morinobu
JOURNAL OF MOVEMENT DISORDERS, 2025,
[25] Potential Psychosis Induced by a Sustained High Plasma Levodopa Concentration Due to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson's Disease: A Case Report
Tezuka, Toshiki
Nukariya, Tomonori
Kizuka, Yuta
Okusa, Shohei
Okochi, Ryotaro
Sakai, Yuto
Nihei, Yoshihiro
Nakahara, Jin
Seki, Morinobu
JOURNAL OF MOVEMENT DISORDERS, 2024, 17 (04) : 453 - 455
[26] Daily Time-Course of Efficacy of Continuous Subcutaneous Infusion of Foslevodopa/foscarbidopa in Advanced Parkinson's Disease Patients from a Phase 1b Study
Stodtmann, S.
Rosebraugh, M.
Robieson, W.
Facheris, M.
MOVEMENT DISORDERS, 2020, 35 : S421 - S421
[27] Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial
Soileau, Michael J.
Aldred, Jason
Budur, Kumar
Fisseha, Nahome
Fung, Victor Sc
Jeong, Anna
Kimber, Thomas E.
Klos, Kevin
Litvan, Irene
O'Neill, Daniel
Robieson, Weining Z.
Spindler, Meredith A.
Standaert, David G.
Talapala, Saritha
Vaou, Eleni Okeanis
Zheng, Hui
Facheris, Maurizio F.
Hauser, Robert A.
LANCET NEUROLOGY, 2022, 21 (12): : 1099 - 1109
[28] Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
Jason Aldred
Eric Freire-Alvarez
Alexander V. Amelin
Angelo Antonini
Bruno Bergmans
Filip Bergquist
Manon Bouchard
Kumar Budur
Camille Carroll
K. Ray Chaudhuri
Susan R. Criswell
Erik H. Danielsen
Florin Gandor
Jia Jia
Thomas E. Kimber
Hideki Mochizuki
Weining Z. Robieson
Amy M. Spiegel
David G. Standaert
Saritha Talapala
Maurizio F. Facheris
Victor S. C. Fung
Neurology and Therapy, 2023, 12 (6) : 1937 - 1958
[29] Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (vol 12, 1937, 2023)
Aldred, Jason
Freire-Alvarez, Eric
Amelin, Alexander V.
Antonini, Angelo
Bergmans, Bruno
Bergquist, Filip
Bouchard, Manon
Budur, Kumar
Carroll, Camille
Chaudhuri, K. Ray
Criswell, Susan R.
Danielsen, Erik H.
Gandor, Florin
Jia, Jia
Kimber, Thomas E.
Mochizuki, Hideki
Robieson, Weining Z.
Spiegel, Amy M.
Standaert, David G.
Talapala, Saritha
Facheris, Maurizio F.
Fung, Victor S. C.
NEUROLOGY AND THERAPY, 2023, 12 (06) : 1959 - 1960
[30] Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial (vol 21, pg 1099, 2022)
Soileau, M. J.
Aldread, J.
Budur, K.
LANCET NEUROLOGY, 2023, 22 (03): : E5 - E5

← 1 2 3 4 5 →